MIR200A (MicroRNA 200a)

Furthermore, members of the miR‑200 family have potential as diagnostic and prognostic biomarkers and are closely linked to chemotherapy resistance. The present review aims to provide novel insights and a theoretical foundation for the diagnosis, treatment, and deeper investigation of BC by comprehensively examining the functional mechanisms of the miR‑200.

Overall, these findings indicate that AVO and EHS trigger an early stress-adaptive response involving PI3K/AKT and MAPK/ERK signaling and modulation of apoptosis-related pathways. Such responses reflect a dynamic balance between cellular adaptation and pro-apoptotic signaling, which may become relevant under prolonged or higher-intensity exposure conditions.

Different miRNA families, particularly miR-200 and miR-30, have the potential to act as key biomarkers for ovarian cancer prognosis. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024579585, identifier CRD42024579585.

The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 29: 1579‑1587, 2013; DOI: 10.3892/or.2013.2267].

Although HEK-293 cytotoxicity and previously reported nephrotoxic effects warrant caution, these results support the potential of andrographolide as an adjuvant phytochemical capable of modulating clinically relevant miRNAs in prostate cancer. Future studies investigating optimized delivery systems and validating direct miRNA targets may help advance andrographolide toward safer and more targeted therapeutic applications.

We identify miR-224-5p as a fibroinflammatory activity indicator for early cirrhosis detection and miR-200a-3p as a synergistic enhancer of AFP for non-invasive HCC diagnosis, establishing a dual miRNA signature that spans the HBV disease continuum and addresses critical gaps in current risk stratification. These findings highlight the potential of specific serum miRNAs as non-invasive biomarkers for monitoring disease progression and improving the differential diagnosis during the process of HBV-related liver diseases.

Exploiting this axis may enhance early diagnosis and therapy. Future work should integrate redox profiling with miRNA expression to personalize treatment and assess performance relative to existing modalities like PARP inhibitors.

Future research is focusing on integrated multi-omics strategies, the development of wearable real-time monitoring devices, and establishing regulatory frameworks to better facilitate clinical implementation. Addressing these issues may improve the reliability and accessibility of saliva-based diagnostics for OSCC, particularly in low-resource and high-risk populations.

Among the miRNA alterations associated with stage I adenocarcinoma in nonsmokers, we found alterations in all 5 miR-200 family members (miR-200b, miR-200a, miR-141, miR-429, and miR-200c). Our identification of miRNA alterations associated with early-stage lung adenocarcinoma in nonsmokers, especially alterations in the miR-200 family, suggests that these miRNAs may play a unique role in the early stages of lung carcinogenesis and progression in nonsmokers and that they may be useful as markers for the early detection of lung cancer.

These findings define a crucial role for CPS1 in lung cancer metastasis. Targeting CPS1 may offer a valuable therapeutic intervention strategy against metastatic lung cancer.

These findings reveal a TMAO-HULC signaling axis that positively influences the levels of oncogenic miRNAs. However, since a single cell line model was used in this study, it needs for further investigation across diverse CRC cell lines to confirm its generalizability.

Circulating miRNA signatures represent promising non-invasive biomarkers for early PM detection and prognostic stratification, particularly in epithelioid cases. Incorporation of these biomarkers into clinical workflows could pave the way for more personalized treatment strategies and optimize patient selection for surgery.